Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent vs Sequential Rituximab with EPOCH in HIV-NHL
NCT00049036Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2003
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in B-cell non-Hodgkin lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment at 60 days. Started Mar 2003; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00049036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049036.